Advertisement

Liver Failure and Jaundice in the Intensive Care Unit

  • Paul Ellis Marik

Abstract

Liver disease has two major components: hepatocyte failure and portal hypertension. The clinical picture of chronic liver disease is frequently dominated by the compilations of portal hypertension. On the other hand, the clinical picture of acute/fulminant hepatic failure is dominated by hepatocyte failure (Table 28–1). Fulminant hepatic failure (FHF) is potentially reversible and must be distinguished from chronic liver failure, an irreversible condition that develops over months to years. Patients with FHF are best managed in tertiary care facilities that have extensive experience in treating such patients, with facilities for orthotopic liver transplantation.

Keywords

Portal Hypertension Hepatic Encephalopathy Orthotopic Liver Transplantation Acute Liver Failure Fulminant Hepatic Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Selected References

  1. 1.
    Canalese J, Gimson AE, Davis C, et al. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. Gut. 1982;23:625–629.PubMedCrossRefGoogle Scholar
  2. 2.
    Jalan R, Damink SW, Deutz NE, Lee A, Hayes PC. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure. Lancet. 1999;354:1164–1168.PubMedCrossRefGoogle Scholar
  3. 3.
    Mas A, Rodes J. Fulminant hepatic failure. Lancet. 1997;349:1081–1085.PubMedCrossRefGoogle Scholar
  4. 4.
    Morgan TR, Moritz TE, Mendenhall CL, Haas R. Protein consumption and hepatic encephalopathy in alcoholic hepatitis. VA Cooperative Study group.J Am Coll Nutr. 1995;14:152–158.PubMedGoogle Scholar
  5. 5.
    Ramond MJ, Poynard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med. 1992;326:507–512.PubMedCrossRefGoogle Scholar
  6. 6.
    Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. Lancet. 1984;2:493–495.PubMedCrossRefGoogle Scholar
  7. 7.
    Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med. 1997;337:473–479.PubMedCrossRefGoogle Scholar
  8. 8.
    Shakil AO, Mazariegos GV, Kramer DJ. Fulminant hepatic failure. Surg Clin North Am. 1999;79:77–108.PubMedCrossRefGoogle Scholar
  9. 9.
    Staedt U, Leweling H, Gladisch R, et al. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol. 1993;19:424–430.PubMedCrossRefGoogle Scholar
  10. 10.
    Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double- blind study. J Hepatol. 1998;28:856–864.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 2001

Authors and Affiliations

  • Paul Ellis Marik
    • 1
  1. 1.Critical Care MedicineMercy Hospital of PittsburghPittsburghUSA

Personalised recommendations